BioSpace News Archive

GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene™ device.

Reynolds Orthodontics is proud to announce that orthodontist Dr. Mark Reynolds is the only Platinum Plus Invisalign Certified Provider in the Triad (Greensboro, Winston-Salem, and High Point) area of North Carolina. While he also attained this level in 2018, Reynolds remains the only orthodontist in the area to maintain this status for more than one year.

Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a study of its Gene Mediated Cytotoxic Immunotherapy (GMCI™; aglatimagene besadenovec plus prodrug) in combination with the checkpoint inhibitor nivolumab and standard of care (SOC) surgery, radiation and temozolomide.

South Florida-Based Marketing Company CEMG will host CannaDayz this April 2019.

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering.

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the pricing of an underwritten public offering of 1,029,412 shares of its common stock at a public offering price of $17.00 per share.

Caravan Health and the Florida Hospital Association (FHA) have teamed up to strengthen health care for Medicare beneficiaries in Florida

The March issue of United Spinal Association’s New Mobility Magazine features wheelchair-using doctors who have had to contend with medical schools’ outdated technical standards and institutional bias but have nonetheless persevered and succeeded.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020.

Use of IBM Watson for Clinical Trial Matching Expands Health Quest’s Use of AI